创新药概念股盘中走低，舒泰神、前沿生物跌超10%，福元医药跌停，百花医药、亚太药业、万邦德、 百利天恒、睿智医药等多股跌超5%。 ...

每经AI快讯，9月5日，A股早盘创新药概念震荡调整，福元医药跌停，前沿生物跌超10%，百花医药、 济民健康、舒泰神、百利天恒等多股跌超5%。 （文章来源：每日经济新闻） ...

Group 1 - The innovative drug concept sector experienced fluctuations in early trading, with several companies facing significant declines [1] - Fuyuan Pharmaceutical hit the daily limit down, indicating a strong negative market reaction [1] - Frontier Biotech dropped over 10%, reflecting investor concerns in the sector [1] Group 2 - Other companies such as Baihua Pharmaceutical, Jimin Health, Shutaishen, Bailitianheng, and Chengdu Xian Dao also saw declines exceeding 5% [1]

Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the production of Amlodipine Benazepril Capsules, marking a significant milestone for the company in expanding its product offerings [1] Group 1 - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule, indicating a combination therapy for hypertension [1] - The drug registration certificate number is 2025S02582, which formalizes the approval process [1]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

证券之星消息，9月4日化学制药板块较上一交易日下跌2.93%，南新制药领跌。当日上证指数报收于 3765.88，下跌1.25%。深证成指报收于12118.7，下跌2.83%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 870656 | 海景药业 | 21.20 | 9.67% | 5.56万 | | 1.13亿 | | 688356 | 键凯科技 | 99.80 | 7.60% | 4.44万 | | 4.55 Z | | 6801089 | 福元医药 | 27.13 | 6.98% | 38.49万 | | 10.55 Z | | 301075 | 多瑞医药 | 40.87 | 5.88% | 6.56万 | | 2.68亿 | | 002365 | 永安药业 | 18.98 | 5.33% | 39.70万 | | 7.52亿 | | 000908 | ST景峰 | 5.78 | 5.09% | 10.14万 | 5846.85万 | | | ...

该药品获得《药品注册证书》，将进一步丰富公司产品线，有助 于提升公司产品的市场竞争力。 证券代码：601089 证券简称：福元医药 公告编号：临 2025-062 北京福元医药股份有限公司 关于氨氯地平贝那普利胶囊获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的氨氯地平贝 那普利胶囊（规格：每粒含苯磺酸氨氯地平 5mg（按 C₂?H₂?ClN₂O?计） 与盐酸贝那普利 10mg）（以下简称"该药品"）《药品注册证书》（证 书编号：2025S02582），批准该药品生产。现将相关情况公告如下： 一、药品注册证书主要内容 药品通用名称：氨氯地平贝那普利胶囊 药品名称 英文名/拉丁名：Amlodipine Besilate and Benazepril Hydrochloride Capsules 剂型 胶囊剂 注册分类 化学药品3类 每粒含苯磺酸氨氯地平5mg（按C₂?H₂?ClN₂O? 规格 计） ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-062 北京福元医药股份有限公司 关于氨氯地平贝那普利胶囊获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的氨氯地平贝 那普利胶囊（规格：每粒含苯磺酸氨氯地平 5mg（按 C₂₀H₂₅ClN₂O₅计） 与盐酸贝那普利 10mg）（以下简称"该药品"）《药品注册证书》（证 书编号：2025S02582），批准该药品生产。现将相关情况公告如下： | | 根据《中华人民共和国药品管理法》及有关规 定，经审查，本品符合药品注册的有关要求， | | --- | --- | | | 批准注册，发给药品注册证书。质量标准、说 | | 审批结论 | 明书、标签及生产工艺照所附执行。药品生产 | | | 企业应当符合药品生产质量管理规范要求方可 | | | 生产销售。 | | 上市许可持有人 | 北京福元医药股份有限公司 | | 生产企业 | 北京 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating a significant milestone for the company in the hypertension treatment market [1]. Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Amlodipine Benazepril Capsules, which contain 5mg of Amlodipine and 10mg of Benazepril per capsule [1]. - This product is intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those who are switching from separate Amlodipine and Benazepril tablets [1]. Group 2: Market Context - Amlodipine Benazepril was originally developed by Novartis and was first approved in the United States in March 1995 [1]. - The original manufacturer’s version of Amlodipine Benazepril has not yet been launched in China, presenting a potential market opportunity for Fuyuan Pharmaceutical [1].

福元医药公告，近日收到国家药监局颁发的氨氯地平贝那普利胶囊（规格：每粒含苯磺酸氨氯地平5mg （按C H ClN O 计）与盐酸贝那普利10mg）药品注册证书，批准该药品生产。该药品用于治疗高血 压，由诺华研发，最早于1995年3月在美国获批上市，本品适用于单独服用氨氯地平或贝那普利不能满 意控制血压的患者，或同时服用氨氯地平片和贝那普利片的替代治疗。公司于2024年3月21日获得申报 受理通知书，并于近日获得国家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》，视 同通过一致性评价。 ...